-
Thematic Analysis
NewGeneric Drugs – Physician Perspective – Thematic Intelligence
Generic drugs are touted as an effective cost-containment measure for healthcare systems that often have outdated or ineffective financing mechanisms. By bypassing the extensive clinical studies required for branded medicines, generic drugs can offer the same therapeutic benefits at a lower price. Nevertheless, even though the uptake of generics is increasing, the concerns regarding product quality, physicians' hesitation to prescribe, and patients’ resistance to switching are seen as some major barriers to the more widespread adoption of generics. Key findings from this...
-
Product Insights
Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Drugs In Development, 2023’, provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Drugs In Development, 2023’, provides an overview of the Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Juvenile Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Juvenile Arthritis - Drugs In Development, 2023’, provides an overview of the Juvenile Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Psoriatic Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psoriatic Arthritis - Drugs In Development, 2023’, provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thalassemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Thalassemia - Drugs In Development, 2023’, provides an overview of the Thalassemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Chronic Urticaria Or Hives – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Urticaria Or Hives - Drugs In Development, 2023’, provides an overview of the Chronic Urticaria Or Hives pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Spinal Muscular Atrophy (SMA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Muscular Atrophy (SMA) - Drugs In Development, 2023’, provides an overview of the Spinal Muscular Atrophy (SMA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hemophilia B (Factor IX Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemophilia B (Factor IX Deficiency) - Drugs In Development, 2023’, provides an overview of the Hemophilia B (Factor IX Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia B (Factor IX Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Drugs In Development, 2023’, provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...